Effects of DDAVP (1-deamino-8-D arginine vasopressin) infusion on parameters of hemostasis in patients with liver cirrhosis

Effects of DDAVP (1-deamino-8-D arginine vasopressin) infusion on parameters of hemostasis in patients with liver cirrhosis - DDAVP in cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39451

Enrollment

Registered

2012-06-27

Start date

2012-07-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver failure liver fibrosis

Interventions

Patients will be administered a single dose of DDAVP (0.3 µg/kg, intravenously) Blood samples (10 ml, into trisodiumcitrate) will be taken just before infusion, and 1, 3, 6, and 24 hours after infus

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Research group: - Leeftijd > 18 yrs - Non-cholestatic cirrhosis, with moderate to severe disease (Child B or C) - Schedukled to visit the policlinic hepatology for routine check-up - Informed consent Control group (samples obtained in Erasmus MC Rotterdam for different research project) - age>18 yrs - hemophilia type A - Informed consent

Exclusion criteria

Exclusion criteria: - Age

Design outcomes

Primary

Measure	Time frame
Study endpoint will be time-dependent changes in laboratory parameters in patients with cirrhosis compared to these changes in patients with hemophilia, in which the efficacy of DDAVP has been well established.	—

Secondary

Measure	Time frame
To elucidate possible mechanisms involved in the supranormal levels of VWF and factor VIII in patients with liver cirrhosis.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)